Liron Bar‐Peled

The paper introduces molecular COUPLrs to systematically target protein complexes, identifying new glue classes and their interactions in cancer cell lines.

The paper identifies oxidative protein states as drivers of metastatic fitness in lung cancer by linking ROS-regulated protein modifications to mitochondrial function and metastasis.

This study shows that MFSD12 is essential for mouse embryonic development by supplying reduced cysteine to lysosomes, and cysteamine treatment rescues Mfsd12 knockout mice.

The paper shows that modified adenosines from RNA catabolism are sequentially metabolized to prevent toxicity and maintain metabolic balance.

This paper identifies UM171 as a molecular glue that promotes degradation of HDAC1/2 complexes by inducing asymmetric interactions between KBTBD4 and HDAC1.

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

The paper identifies a nucleus-to-mitochondria ROS sensing pathway involving CHK1 and SSBP1 that mediates resistance to platinum-based chemotherapies in ovarian cancers.

The paper shows NRF2 activation in KEAP1 wildtype lung cancers causes NADH-reductive stress, making them vulnerable to Complex I inhibition.